SK Biopharm Reports 2Q Operating Loss of 40.1 Billion KRW... Deficit Reduced
[Asia Economy Reporter Kwon Jaehee] SK Biopharm announced on the 11th that its consolidated operating loss for the second quarter of this year was tentatively estimated at 40.072 billion KRW, showing a decrease in the deficit compared to the same period last year (65.081 billion KRW).
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- Dramatic Agreement Reached on Eve of Samsung Electronics General Strike... Minister Kim Young-hoon: "Showcased Korea's Strength in Dialogue" (Update)
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Sales increased by 122.92% to 53.433 billion KRW. Net loss was 45.4 billion KRW, with the deficit narrowing by 32.23%.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
